Pibrentasvir

Independent reference data for Pibrentasvir (CAS 1353900-92-1), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Indicated for the treatment of adult patients with acute and chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.Breast Feeding; Lactation; Milk, Human; Antiviral Agents; NS5A Inhibitors

Synonyms and trade names

Pibrentasvir; 1353900-92-1; ABT-530; A-1325912.0; 2WU922TK3L; DTXSID601027946; pibrentasvirum; RefChem:863096; DTXCID501513514; 829-351-5; Pibrentasvir [USAN]; ABT 530; Abt530; D10816; Pibrentasvir (ABT-530); C57H65F5N10O8

GHS hazard classification

Reported hazard statements	H315 (100%), H319 (100%), H335 (100%), H413 (100%)

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

What the public record says

Pibrentasvir · CAS 1353900-92-1 · C57H65F5N10O8. UNII 2WU922TK3L. Solubility: <0.1 mg/mL.

Source: PubChem / Wikidata; the batch COA governs where values differ.